Adaptive Biotechnologies Corp expected to post a loss of 35 cents a share - Earnings Preview

Adaptive Biotechnologies

11/02/2023 02:15

* Adaptive Biotechnologies Corp  ADPT.OQ   ADPT.O  is
expected
to show a rise in quarterly revenue when it reports  results on
February 14. 
    * The Seattle Washington-based  company is expected to
report  a
45.7% increase in revenue to $55.275 million from $37.93 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Adaptive
Biotechnologies
Corp is for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adaptive
Biotechnologies Corp is $13.5​, above​ its last closing price
of $8.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.37       -0.38      -0.32     Beat    14.9
 Jun. 30 2022  -0.41       -0.43      -0.37     Beat    14
 Mar. 31 2022  -0.45       -0.46      -0.44     Beat    4.1​
 Dec. 31 2021  -0.47       -0.45      -0.43     Beat    4.7
 ​​Sep.        -0.42       -0.42      -0.40     Beat    5
 30 2021                                                
 Jun. 30 2021  -0.42       -0.43      -0.35     Beat    18.1​
 Mar. 31 2021  -0.41       -0.41      -0.29     Beat    29
 Dec. 31 2020  -0.29       -0.29      -0.33     Missed  -12.7
 This summary was machine generated February 11 at 02:15 GMT. 
All figures in US dollars  unless otherwise stated